Keryx Biopharmaceuticals to Present at BioCentury's NewsMakers in the Biotech Industry ... ( NEW YORK Oct. 19 /- Keryx Biopharmace...)

Keryx Biopharmaceuticals to Present at BioCentury's NewsMakers in the Biotech Industry Conference

Date:10/19/2010

NEW YORK, Oct. 19 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at BioCentury's NewsMakers in the Biotech Industry Conference, being held at the Millennium Broadway Hotel and Conference Center in New York City. Mr. Bentsur's presentation is scheduled to take place on Friday, October 22, 2010, at 2:00 p.m.

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of each webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex(TM) (ferric citra
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:5/21/2013)... May 21, 2013 Kepner-Tregoe (KT), the ... that 13-year veteran Chris Geraghty ... experience includes more than 20 years serving the ... manufacturing organizations. He succeeds Ray Baxter ... Kepner-Tregoe,s Chairman of the Board and CEO. ...

(Date:5/21/2013)... , May 21, 2013 Armada Health ... of the new Armada corporate website ( www.armadahealthcare.com ... communicate Armada,s unique and first-to-market services and its ... focused on the specialty pharmacy industry. ... of the Armada business model in delivering an ...

(Date:5/21/2013)... May 21, 2013 Hurel Corporation ("Hurel"), a ... cell-based assay platforms, today announced the appointment of ... the Company,s Board of Directors. Dr. MacDonald is the ... Schering-Plough Research Institute ("SPRI"), which was the pharmaceutical development ... Merck & Co. in 2009. Over a ...

Breaking Medicine Technology:Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2 Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3 Armada Announces New Corporate Website to Showcase Expanded Services to Specialty Pharmacy Marketplace 2 Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2

[0] Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer [0] Armada Announces New Corporate Website to Showcase Expanded Services to Specialty Pharmacy Marketplace [0] Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors

... EORTC 40983 (EPOC),Intergroup Study Results, CHICAGO, June ... phase III EORTC 40983 Intergroup study, or ... peri-operative (pre and post,surgery) FOLFOX4 (Eloxatin(R) (oxaliplatin ... for colon cancer,5-fluorouracil/leucovorin (5-FU/LV)) given to patients ...

... Phase II Study Results Presented at Society ... 04, 2007 /PRNewswire-FirstCall/ --,Immunomedics, Inc. , a ... treat cancer and other serious,diseases, today announced ... with the radioisotope,iodine-131, was found to be ...

The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases

(Date:5/21/2013)... (PRWEB) May 21, 2013 HealthSmart continues ... expanding national presence has required the hiring of new ... HealthSmart is pleased to announce that Dawn Powell has ... serving as the Director of Account Management in the ... offices in Irving, Texas. With extensive client management, employee ...

(Date:5/21/2013)... Arizona State University is seeking ... develop their ideas into solutions, products and services ... university is recruiting participants for AREA48 (Applied Regional ... provides early-stage entrepreneurs with opportunities to access human ... anyone, ASU is particularly seeking participation from retirees, ...

(Date:5/21/2013)... Phoseon Technology will present their advanced ... Annual IMI European Ink Jet Conference (June 5-6, ... continues to invest in product development to enable breakthrough ... LED curing in printing applications. Phoseon currently has ... offering both air cooled and water cooled solutions to ...

(Date:5/21/2013)... Modern couples have countless strains on ... Sexuality and Relationship Workshops, couples are learning the ... habits for their relationship. There are both private ... individuals at Texas Counseling. Their goal is to ... to develop long term solutions. , Developing ...

(Date:5/21/2013)... Defense Serum Repository (DoDSR), University of Cincinnati (UC) researchers ... disease (IBD), which could help with earlier diagnosis and ... , This finding, the first of its kind and ... via podium presentation by staff from Walter Reed National ... held May 18-21 in Orlando, Fla. , The ...

Breaking Medicine News(10 mins):Health News:New Talent Joins the HealthSmart Account Management Team 2 Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 2 Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 3 Health News:ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors 4 Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2 Health News:Biomarkers discovered for inflammatory bowel disease 2

[0] New Talent Joins the HealthSmart Account Management Team [0] ASU Launches Summer Program for Aspiring Entrepreneurs, Innovators and Inventors [0] Phoseon Technology Presents the Leading UV LED Curing Solutions at IMI European Ink Jet Conference [0] Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships [0] Biomarkers discovered for inflammatory bowel disease

... CORVALLIS, Ore. Researchers have developed a type of wearable, ... heart rate and respiration at the same time it records ... diagnostics and patient care. The device is just two ... contact with the skin and can operate for a week ...

... magnetic resonance equipment available, researchers at the University of ... structure of biological molecules -- potentially leading to new ... cancer and Alzheimer,s disease. The findings appear in ... and Journal of Biological Chemistry "These ...

... -- About one million packets of birth control pills are ... of a packaging error that could reduce the effectiveness of ... 14 lots of Lo/Ovral-28 tablets and 14 lots of generic ... Pfizer discovered that some blister packs may contain either too ...

... Kathleen Doheny HealthDay Reporter , WEDNESDAY, Feb. 1 ... pauses in breathing during sleep, is already known to boost ... apnea to so-called silent strokes, in which there is tissue ... study, researchers found that rapid memory loss before a stroke ...

... (HealthDay News) -- Many adults whose parents suffered a stroke ... middle age that may precede a stroke, a new study ... age of 61 who underwent MRI brain scans to assess ... white matter lesions and other signs of aging or damage ...

... multiforme (GBM) is the most common of all malignant ... GBM have a poor prognosis because it is a ... to current therapies. New therapeutic approaches are therefore much ... University of California, San Francisco, have now identified a ...

Cached Medicine News:Health News:Protein structures give disease clues 2 Health News:Pfizer Recalls 1 Million Packets of Birth Control Pills 2 Health News:Sleep Apnea May Be Tied to 'Silent' Strokes, Study Finds 2 Health News:Sleep Apnea May Be Tied to 'Silent' Strokes, Study Finds 3 Health News:Adult Children of Stroke Sufferers May Show Signs of Brain Aging, Too 2

'Life and activity monitor' provides portable, constant recording of vital signs Protein structures give disease clues Pfizer Recalls 1 Million Packets of Birth Control Pills Sleep Apnea May Be Tied to 'Silent' Strokes, Study Finds Adult Children of Stroke Sufferers May Show Signs of Brain Aging, Too A thought-provoking new therapeutic target for brain cancer?

The SleepStyle 600 series with ThermoSmart delivers humidification with anti-rainout benefits. ThermoSmart technology offers a heated breathing tube that allows the constant delivery of optimal level...

... offers a display, ramp capabilities ... also has features that make ... session meter records the number ... than four hours - giving ...

... CPAP System is the smallest and lightest ... the market. It is designed to help ... while complying with therapy. The GoodKnight 420S ... date/time usage data. It also detects persistent ...

Micro-hematocrit tubes available in multiple sizes and additives for a wide range of capillary blood collection....

Medicine Products:

SleepStyle 604 REMstar Plus GoodKnight 420S CPAP System Safe-T-Fill® Micro Hematocrit Tubes